சீரம் நிறுவனம் பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சீரம் நிறுவனம் பாரத் பயோடெக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சீரம் நிறுவனம் பாரத் பயோடெக் Today - Breaking & Trending Today

First Wave and the Aftermath: What Went Wrong


First Wave and the Aftermath: What Went Wrong
Chander Sangra
Henry Ford once said, “The only real mistake is the one from which we learn nothing.” The experience alone does not necessarily lead to learning; it is the reflection that makes sense of the experience to us and hence makes the experience meaningful for us. John Dewey rightly observed, “We don’t learn from experience, we learn from reflecting on experience.” If we had reflected on the experiences from the first wave of the Covid-19 Pandemic, we wouldn’t have been facing it as it stands now. It is hard to believe that a country which surprised the world by swaying the spread dramatically is facing a disparate scenario in the second phase. While the epidemiologists confidently predicted millions of deaths by August 2020, India remained focused and unitedly fought the battle under a strong leadership at the centre along with the collective hardships of the entire government machinery across the nation. L ....

Andhra Pradesh , United States , United Kingdom , Tamil Nadu , Chander Sangra , John Dewey , Henry Ford , Centre Response , Election Commission , Serum Institute Bharat Biotech , States Governments , State Governments , Protests When Indian , Central Government , West Bengal , Hyderabad Municipal , Vaccines Vaccination , Serum Institute , Bharat Biotech , Behaviour One , Response The Centre , Disaster Management Act , Data Architect , ஆந்திரா பிரதேஷ் , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் ,

Pharma index hits record high as govt launches phase 3 of Covid vaccination


Shares of pharmaceutical companies are in demand at the bourses with Nifty Pharma and the S&P BSE Healthcare indices gaining 2 per cent each and hitting their respective all-time highs on Tuesday as a significant resurge in Covid-19 cases across India led to spike in demand for Covid-related drugs.
Individually, Cipla, Gland Pharma, JB Chemicals and Pharmaceuticals, Max Healthcare, Neuland Laboratories and Apollo Hospital Enterprises hit their respective record highs today. Menawhile, Sun Pharmaceutical Industries, Cadila Healthcare, Glenmark Pharmaceuticals, Panacea Biotech and RPG Lifesicenes are among those that hit 52-week highs in the intra-day trade today.
Investors rushed to buy pharma stocks as the Indian government will open up vaccination to anyone over 18 years of age starting May 1 with greater flexibility on pricing, procurement and administration of vaccines. This opens up the private market for vaccination and provides more leeway to states and private compa ....

Andhra Pradesh , Sun Pharmaceutical Industries , Apollo Hospital Enterprises , Health Canada , Glenmark Pharmaceuticals , Serum Institute Bharat Biotech , Nifty Pharma , Gland Pharma , Max Healthcare , Neuland Laboratories , Cadila Healthcare , Panacea Biotech , Bharat Biotech , Axis Capital , Indian Pharma Market , Vivimed Labs , Morepen Laboratories , Nectar Lifesciences , Chlorpheniramine Maleate Syrup , ஆந்திரா பிரதேஷ் , சூரியன் மருந்து தொழில்கள் , அப்பல்லோ மருத்துவமனை நிறுவனங்கள் , ஆரோக்கியம் கனடா , க்ளேண்மர்க் மருந்துகள் , சீரம் நிறுவனம் பாரத் பயோடெக் , நிஃப்டி பார்மா ,

10% COVID-19 vaccines will be wasted, says Centre; to cost Rs 1,320 crore more


10% COVID-19 vaccines will be wasted, says Centre; to cost Rs 1,320 crore more
Initial 30 crore vaccinations (60 crore doses) planned by the Centre would have cost Rs 13,200 crore. However, need for 66 crore doses raises the cost by Rs 1320 crore
The Centre plans to launch what PM Modi described as the world s biggest vaccination programme in the next one-two weeks
At least 10 per cent of Covid-19 vaccines procured by the Centre may face programmatic wastage , according to the vaccination plan guidelines released by the Ministry of Health and Family Affairs Ministry. This means nearly 10 in every 100 vaccines the Centre will buy from approved vaccine makers such as Serum Institute & Bharat Biotech may suffer damage in different phases of vaccine management. Also, the Centre will have to order 110 vaccines to vaccinate 50 people, considering a two-dose regime and 10 per cent wastage . The wastage of vaccines, despite limited stock available initially, is bound to ha ....

Zydus Cadila , Adar Poonawalla , Ministry Of Health , Serum Institute Bharat Biotech , Family Affairs Ministry , Serum Institute , Serum Institute Of India , Oxford University , Centre Rs , Family Affairs , Bharat Biotech , Wastage Multiplication Factor , Sputnikv Vaccine , Emergency Use Authorisation , Central Pollution Control Board , Covid 19 Vaccines , Waste Vaccines , Vaccine Cost , Covid 19 Vaccines Required For Phase 1 , Total Cost Of Vaccination , Serum Vaccine Cost , ஜய்துச் காடிலா , அடார் பூனாவல்ல , அமைச்சகம் ஆஃப் ஆரோக்கியம் , சீரம் நிறுவனம் பாரத் பயோடெக் , குடும்பம் வாழ்க்கைத்தொழில்கள் அமைச்சகம் ,